185 related articles for article (PubMed ID: 19067728)
1. Use of a GH receptor antagonist (GHRA) to explore the relationship between GH and IGF-I in adults with severe GH deficiency (GHD).
Berg CA; Pokrajac A; Bidlingmaier M; Strasburger CJ; Shalet SM; Trainer PJ
Clin Endocrinol (Oxf); 2009 Mar; 70(3):439-45. PubMed ID: 19067728
[TBL] [Abstract][Full Text] [Related]
2. Acute effect of pegvisomant on cardiovascular risk markers in healthy men: implications for the pathogenesis of atherosclerosis in GH deficiency.
Muller AF; Leebeek FW; Janssen JA; Lamberts SW; Hofland L; van der Lely AJ
J Clin Endocrinol Metab; 2001 Nov; 86(11):5165-71. PubMed ID: 11701672
[TBL] [Abstract][Full Text] [Related]
3. Lowering total plasma insulin-like growth factor I concentrations by way of a novel, potent, and selective growth hormone (GH) receptor antagonist, pegvisomant (B2036-peg), augments the amplitude of GH secretory bursts and elevates basal/nonpulsatile GH release in healthy women and men.
Veldhuis JD; Bidlingmaier M; Anderson SM; Wu Z; Strasburger CJ
J Clin Endocrinol Metab; 2001 Jul; 86(7):3304-10. PubMed ID: 11443205
[TBL] [Abstract][Full Text] [Related]
4. Bone loss is correlated to the severity of growth hormone deficiency in adult patients with hypopituitarism.
Colao A; Di Somma C; Pivonello R; Loche S; Aimaretti G; Cerbone G; Faggiano A; Corneli G; Ghigo E; Lombardi G
J Clin Endocrinol Metab; 1999 Jun; 84(6):1919-24. PubMed ID: 10372687
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of growth hormone (GH) during extended treatment of adult Japanese patients with GH deficiency (GHD).
Chihara K; Kato Y; Kohno H; Takano K; Tanaka T; Teramoto A; Shimatsu A
Growth Horm IGF Res; 2008 Aug; 18(4):307-17. PubMed ID: 18282776
[TBL] [Abstract][Full Text] [Related]
6. Clinical pharmacodynamic effects of the growth hormone receptor antagonist pegvisomant: implications for cancer therapy.
Yin D; Vreeland F; Schaaf LJ; Millham R; Duncan BA; Sharma A
Clin Cancer Res; 2007 Feb; 13(3):1000-9. PubMed ID: 17289896
[TBL] [Abstract][Full Text] [Related]
7. Effects of 36 hour fasting on GH/IGF-I axis and metabolic parameters in patients with simple obesity. Comparison with normal subjects and hypopituitary patients with severe GH deficiency.
Maccario M; Aimaretti G; Grottoli S; Gauna C; Tassone F; Corneli G; Rossetto R; Wu Z; Strasburger CJ; Ghigo E
Int J Obes Relat Metab Disord; 2001 Aug; 25(8):1233-9. PubMed ID: 11477509
[TBL] [Abstract][Full Text] [Related]
8. Effects of fasting and pegvisomant on the GH-releasing hormone and GH-releasing peptide-6 stimulated growth hormone secretion.
Muller AF; Janssen JA; Lamberts SW; Bidlingmaier M; Strasburger CJ; Hofland L; van der Lely AJ
Clin Endocrinol (Oxf); 2001 Oct; 55(4):461-7. PubMed ID: 11678828
[TBL] [Abstract][Full Text] [Related]
9. GH strongly affects serum concentrations of mannan-binding lectin: evidence for a new IGF-I independent immunomodulatory effect of GH.
Hansen TK; Thiel S; Dall R; Rosenfalck AM; Trainer P; Flyvbjerg A; Jørgensen JO; Christiansen JS
J Clin Endocrinol Metab; 2001 Nov; 86(11):5383-8. PubMed ID: 11701711
[TBL] [Abstract][Full Text] [Related]
10. Effects of growth hormone treatment on arginine to asymmetric dimethylarginine ratio and endothelial function in patients with growth hormone deficiency.
Setola E; Monti LD; Lanzi R; Lucotti P; Losa M; Gatti E; Galluccio E; Oldani M; Fermo I; Giovannelli M; Bosi E; Piatti P
Metabolism; 2008 Dec; 57(12):1685-90. PubMed ID: 19013291
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular risk factors in acromegaly before and after normalization of serum IGF-I levels with the GH antagonist pegvisomant.
Sesmilo G; Fairfield WP; Katznelson L; Pulaski K; Freda PU; Bonert V; Dimaraki E; Stavrou S; Vance ML; Hayden D; Klibanski A
J Clin Endocrinol Metab; 2002 Apr; 87(4):1692-9. PubMed ID: 11932303
[TBL] [Abstract][Full Text] [Related]
12. Antitumor activity of the growth hormone receptor antagonist pegvisomant against human meningiomas in nude mice.
McCutcheon IE; Flyvbjerg A; Hill H; Li J; Bennett WF; Scarlett JA; Friend KE
J Neurosurg; 2001 Mar; 94(3):487-92. PubMed ID: 11235955
[TBL] [Abstract][Full Text] [Related]
13. GH sensitivity of GH-deficient adults is dependent on gender but not timing of onset.
Columb B; Smethurst LE; Mukherjee A; Jostel A; Shalet SM; Murray RD
Clin Endocrinol (Oxf); 2009 Feb; 70(2):281-6. PubMed ID: 18702681
[TBL] [Abstract][Full Text] [Related]
14. Relationship between the morphological evaluation of the pituitary and the growth hormone (GH) response to GH-releasing hormone Plus arginine in children and adults with congenital hypopituitarism.
Maghnie M; Salati B; Bianchi S; Rallo M; Tinelli C; Autelli M; Aimaretti G; Ghigo E
J Clin Endocrinol Metab; 2001 Apr; 86(4):1574-9. PubMed ID: 11297586
[TBL] [Abstract][Full Text] [Related]
15. The growth hormone (GH) response to the arginine plus GH-releasing hormone test is correlated to the severity of lipid profile abnormalities in adult patients with GH deficiency.
Colao A; Cerbone G; Pivonello R; Aimaretti G; Loche S; Di Somma C; Faggiano A; Corneli G; Ghigo E; Lombardi G
J Clin Endocrinol Metab; 1999 Apr; 84(4):1277-82. PubMed ID: 10199767
[TBL] [Abstract][Full Text] [Related]
16. Immunoblot studies of the acid-labile subunit (ALS) in biological fluids, normal human serum and in children with GH deficiency and GH receptor deficiency before and after long-term therapy with GH or IGF-I respectively.
Labarta JI; Gargosky SE; Simpson DM; Lee PD; Argente J; Guevara-Aguirre J; Rosenfeld RG
Clin Endocrinol (Oxf); 1997 Dec; 47(6):657-66. PubMed ID: 9497872
[TBL] [Abstract][Full Text] [Related]
17. Growth hormone deficiency (GHD) in adult thalassaemic patients.
Scacchi M; Danesi L; Cattaneo A; Valassi E; Pecori Giraldi F; Argento C; D'Angelo E; Mirra N; Carnelli V; Zanaboni L; Cappellini MD; Cavagnini F
Clin Endocrinol (Oxf); 2007 Nov; 67(5):790-5. PubMed ID: 17608814
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance.
Colao A; Pivonello R; Auriemma RS; De Martino MC; Bidlingmaier M; Briganti F; Tortora F; Burman P; Kourides IA; Strasburger CJ; Lombardi G
Eur J Endocrinol; 2006 Mar; 154(3):467-77. PubMed ID: 16498061
[TBL] [Abstract][Full Text] [Related]
19. The influence of growth hormone replacement on peripheral inflammatory and cardiovascular risk markers in adults with severe growth hormone deficiency.
Deepak D; Daousi C; Javadpour M; Clark D; Perry Y; Pinkney J; Macfarlane IA
Growth Horm IGF Res; 2010 Jun; 20(3):220-5. PubMed ID: 20185347
[TBL] [Abstract][Full Text] [Related]
20. Retesting young adults with childhood-onset growth hormone (GH) deficiency with GH-releasing-hormone-plus-arginine test.
Aimaretti G; Baffoni C; Bellone S; Di Vito L; Corneli G; Arvat E; Benso L; Camanni F; Ghigo E
J Clin Endocrinol Metab; 2000 Oct; 85(10):3693-9. PubMed ID: 11061526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
